These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 8489189

  • 1. Re: Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers.
    Brown GL.
    Ann Plast Surg; 1993 Feb; 30(2):192. PubMed ID: 8489189
    [No Abstract] [Full Text] [Related]

  • 2. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers.
    Mustoe TA, Cutler NR, Allman RM, Goode PS, Deuel TF, Prause JA, Bear M, Serdar CM, Pierce GF.
    Arch Surg; 1994 Feb; 129(2):213-9. PubMed ID: 8304833
    [Abstract] [Full Text] [Related]

  • 3. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
    Ladin D.
    Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
    Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH.
    Wound Repair Regen; 1999 Mar; 7(5):335-46. PubMed ID: 10564562
    [Abstract] [Full Text] [Related]

  • 5. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
    Rees RS, Robson MC, Smiell JM, Perry BH.
    Wound Repair Regen; 1999 Mar; 7(3):141-7. PubMed ID: 10417749
    [Abstract] [Full Text] [Related]

  • 6. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, Lau CY.
    Wound Repair Regen; 2000 Mar; 8(3):162-8. PubMed ID: 10886806
    [Abstract] [Full Text] [Related]

  • 7. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers.
    Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF.
    Lancet; 1992 Jan 04; 339(8784):23-5. PubMed ID: 1345953
    [Abstract] [Full Text] [Related]

  • 8. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS.
    J Foot Ankle Surg; 1999 Jan 04; 38(3):227-31. PubMed ID: 10384364
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ, Smiell JM, Su Y.
    Diabetes Care; 1998 May 04; 21(5):822-7. PubMed ID: 9589248
    [Abstract] [Full Text] [Related]

  • 10. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel.
    Castronuovo JJ, Ghobrial I, Giusti AM, Rudolph S, Smiell JM.
    Am J Surg; 1998 Aug 04; 176(2A Suppl):61S-67S. PubMed ID: 9777974
    [Abstract] [Full Text] [Related]

  • 11. Treatment of recalcitrant lower extremity ulcers with topical becaplermin.
    Davis MD, Weed B, Felty CL, Rooke T.
    J Am Acad Dermatol; 2004 Jun 04; 50(6):981-2. PubMed ID: 15153913
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of stingray injury with topical becaplermin gel.
    Baldinger PJ.
    J Am Podiatr Med Assoc; 1999 Oct 04; 89(10):531-3. PubMed ID: 10546426
    [Abstract] [Full Text] [Related]

  • 13. Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel).
    Victor-Vega C, Desai A, Montesinos MC, Cronstein BN.
    Inflammation; 2002 Feb 04; 26(1):19-24. PubMed ID: 11936752
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
    Wieman TJ.
    Am J Surg; 1998 Aug 04; 176(2A Suppl):74S-79S. PubMed ID: 9777976
    [Abstract] [Full Text] [Related]

  • 16. Original articles: ease of wound closure as an endpoint of treatment efficacy.
    Robson MC, Maggi SP, Smith PD, Wassermann RJ, Mosiello GC, Hill DP, Cooper DM.
    Wound Repair Regen; 1999 Aug 04; 7(2):90-6. PubMed ID: 10231510
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Becaplermin and necrobiosis lipoidicum diabeticorum: results of a case control pilot study.
    Stephens E, Robinson JA, Gottlieb PA.
    J Diabetes Complications; 2001 Aug 04; 15(1):55-6. PubMed ID: 11259927
    [Abstract] [Full Text] [Related]

  • 19. Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers.
    Robson MC, Phillips LG, Thomason A, Altrock BW, Pence PC, Heggers JP, Johnston AF, McHugh TP, Anthony MS, Robson LE.
    Ann Plast Surg; 1992 Sep 04; 29(3):193-201. PubMed ID: 1524367
    [Abstract] [Full Text] [Related]

  • 20. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor.
    Metz BJ, Rubenstein MC, Levy ML, Metry DW.
    Arch Dermatol; 2004 Jul 04; 140(7):867-70. PubMed ID: 15262700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.